SCHEMBL1103407

SCHEMBL1103407

Cc1cc(-c2c3ccccc3c(-c3ccccc3)c3c2cnc2ccccc23)cc(C)c1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
HTT P42858 3/20 0.43
MAPT P10636 3/20 0.43
NPSR1 Q6W5P4 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ACHE P22303 1/20 0.43
HPGD P15428 3/20 0.41
TOP2A P11388 1/20 0.40
PSMB5 P28074 1/20 0.38
TLR7 Q9NYK1 1/20 0.38
ESR1 P03372 2/20 0.38
ESR2 Q92731 2/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
LMNA P02545 2/20 0.38
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103263 0.96 TOP2A (0.43) ALDH1A1HTTMAPTNPSR1SMN1; SMN2
SCHEMBL13512023 0.90 TOP2A (0.39) ALDH1A1HTTMAPTNPSR1SMN1; SMN2
SCHEMBL1103403 0.88 NPC1 (0.47) ALDH1A1HTTMAPTNPSR1SMN1; SMN2
SCHEMBL1103400 0.87 ALDH1A1 (0.47) ALDH1A1HTTMAPTNPSR1SMN1; SMN2
SCHEMBL1103411 0.87 ALDH1A1 (0.52) ALDH1A1HTTMAPTNPSR1SMN1; SMN2
SCHEMBL1105452 0.87 ESR1 (0.43) ALDH1A1HTTMAPTNPSR1SMN1; SMN2
SCHEMBL1103530 0.86 MET (0.38) ALDH1A1MAPTSMN1; SMN2ACHEHPGD
SCHEMBL1103377 0.85 ESR1 (0.41) ALDH1A1HTTMAPTNPSR1SMN1; SMN2
SCHEMBL1103491 0.85 ESR1 (0.42) ALDH1A1HTTMAPTNPSR1SMN1; SMN2
SCHEMBL1103449 0.85 ESR1 (0.42) ALDH1A1HTTMAPTNPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 ALDH1A1 1015/4885HTT 4390/4885MAPT 3162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.